Copaxone®
Quick Facts
Copaxone® favors Th2 cells which quiet inflammation and help block T cells that damage myelin in the central nervous system.
Self-injected under the skin
Daily or three times per week, depending on dosage
Relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS
Potential Benefit:
In clinical trials, Copaxone® was compared to placebo and showed:
- Approximately 29% fewer relapses
- 35-40% reduction in new and enlarging T2 lesions
- 40-45% reduction in gadolinium-enhancing T1 lesions
Disability progression over 10 years was stable or improved.
Common Potential Side Effects
Nausea, injection site reactions. lipoatrophy (injection site indentations in the skin).
Prescription Assistance:
For assistance finding additional resources that might help cover the costs of your prescription, contact MSAA.
DRUGMAKER
Teva
HOW Copaxone® WORKS
Copaxone® (glatiramer acetate) is a synthetic protein that chemically resembles a protein found in myelin. Copaxone modifies immune processes that favor Th2 cells that quiet inflammation and blocks T cells that damage myelin in the central nervous system.
FDA-Approved
Copaxone® was FDA-approved in 1996. It is approved to treat relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary-progressive disease, in adults.
Potential Side Effects
Injection-site skin reaction and occasional systemic reaction. This occurs at least once in about 10% of people tested. Possible reactions occur about 5-15 minutes after injection. Symptoms may include anxiety, dizziness, depression, flushing, palpitations, chest tightness, shortness of breath. Symptoms are typically short lived, do not affect your health and do not require specific intervention.
OTHER KEY INFORMATION
No testing is required before or while taking Copaxone®
This treatment is also available in generic form under the brand name Glatopa (developed by Sandoz) and as Generic Glatiramer Acetate (developed by Viatris). These generic options are administered in the same way and in the same dosage as Copaxone.